On November 22, 2024, Christine Cvijic, President and Chief Financial Officer of Neurogene Inc, purchased 24,000 shares of the company. Following this transaction, the insider now owns a total of 76,844 shares. The transaction details are available in the SEC Filing.
Neurogene Inc (NGNE, Financial) is a biotechnology company focused on developing life-changing genetic medicines for patients and families affected by rare neurological diseases. The company aims to address unmet medical needs through innovative therapies.
The insider's recent purchase is part of a broader trend within the company. Over the past year, there have been two insider buys and zero insider sells, indicating a positive sentiment among company insiders.
On the day of the purchase, shares of Neurogene Inc were trading at $20.48 each, resulting in a market cap of $331.483 million. This transaction reflects the insider's confidence in the company's future prospects.
For more information on the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's financial performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
